{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:56:46Z","timestamp":1793501806576,"version":"4.5.0"},"reference-count":595,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005881","name":"Ministry of Culture and Innovation","doi-asserted-by":"publisher","award":["2024-1.1.1-KKV_F\\u00D3KUSZ-2024-00022"],"award-info":[{"award-number":["2024-1.1.1-KKV_F\\u00D3KUSZ-2024-00022"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["K128123"],"award-info":[{"award-number":["K128123"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"National Research Development and Innovation Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pharmr.2026.100157","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:03:52Z","timestamp":1786946632000},"page":"100157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Application of human liver cell models in drug development and toxicity studies: The role of membrane transporters"],"prefix":"10.1016","volume":"78","author":[{"given":"Edit","family":"Szab\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-4606","authenticated-orcid":false,"given":"\u00c1gnes","family":"Telbisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsa","family":"Erdei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7533-5764","authenticated-orcid":false,"given":"Kiara Gitta","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Homolya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-4539","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Sarkadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-8139","authenticated-orcid":false,"given":"\u00c1gota","family":"Ap\u00e1ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1023\/B:PHAM.0000026420.79421.8f","article-title":"The complexities of hepatic drug transport: current knowledge and emerging concepts","volume":"21","author":"Chandra","year":"2004","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/17425255.4.4.363","article-title":"The role of hepatic transporters in drug elimination","volume":"4","author":"Funk","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ddtec.2004.11.006","article-title":"Screening for the role of transporters in hepatic and renal drug handling","volume":"1","author":"Masereeuw","year":"2004","journal-title":"Drug Discov Today Technol"},{"issue":"suppl 7","key":"10.1016\/j.pharmr.2026.100157_bib4","first-page":"S11","article-title":"Role of hepatic drug transporters in drug development","volume":"56","author":"Liu","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"International Transporter Consortium","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib7","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.apsb.2022.03.009","article-title":"Recent advances in the translation of Drug Metabolism and Pharmacokinetics science for drug discovery and development","volume":"12","author":"Lai","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/clpt.2013.86","article-title":"Transporters in drug development and clinical pharmacology","volume":"94","author":"Giacomini","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/clpt.2009.236","article-title":"The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA","volume":"87","author":"Huang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib10","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cpt.1224","article-title":"The international transporter consortium: summarizing advances in the role of transporters in drug development","volume":"104","author":"Giacomini","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib11","article-title":"Drug transporters: regulatory guidance from ICH, USFDA, EMA and PMDA","volume":"14","author":"Tang","year":"2023","journal-title":"J Pharmacogenom Pharmacoproteomics"},{"key":"10.1016\/j.pharmr.2026.100157_bib12","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.12688\/f1000research.9466.1","article-title":"Recent advances in understanding hepatic drug transport","volume":"5","author":"Stieger","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.04.018","article-title":"Drugs and hepatic transporters: a review","volume":"154","author":"Jetter","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100157_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/dmd.112.049312","article-title":"Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement","volume":"41","author":"Grime","year":"2013","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/dmd.114.061580","article-title":"Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"517","key":"10.1016\/j.pharmr.2026.100157_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5516","article-title":"Reproducing human and cross-species drug toxicities using a Liver-Chip","volume":"11","author":"Jang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1080\/00498254.2018.1512017","article-title":"Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans","volume":"49","author":"Liao","year":"2019","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/d41573-025-00052-8","article-title":"Insights into new approach methodology innovation: an EMA perspective","volume":"24","author":"Edwards","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib21","article-title":"Organoids and organs-on-chips: recent advances, applications in drug development, and regulatory challenges","volume":"6","author":"Zhou","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib23","first-page":"1759","article-title":"Hepatic differentiation of human iPSCs in different 3D models: a comparative study","volume":"40","author":"Meier","year":"2017","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmr.2026.100157_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120529","article-title":"Generation of uniform liver spheroids from human pluripotent stem cells for imaging-based drug toxicity analysis","volume":"269","author":"Lee","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib25","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1038\/s41467-023-39311-w","article-title":"Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages","volume":"14","author":"Groeger","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib26","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ad5766","article-title":"Human iPSC-derived liver co-culture spheroids to model liver fibrosis","volume":"16","author":"Cools","year":"2024","journal-title":"Biofabrication"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227751","article-title":"The importance of transporters and cell polarization for the evaluation of human stem cell-derived hepatic cells","volume":"15","author":"T\u00f6r\u00f6k","year":"2020","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411592","article-title":"Pluripotent stem cell-derived hepatocyte-like cells: induction methods and applications","volume":"24","author":"Luo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100157_bib29","article-title":"Advances, challenges and future applications of liver organoids in experimental regenerative medicine","volume":"11","author":"Gong","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/pgs.11.53","article-title":"Pharmacogenetics of drug transporters in the enterohepatic circulation","volume":"12","author":"Stieger","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib31","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/pharmaceutics15010029","article-title":"Role of hepatocyte transporters in drug-induced liver injury (DILI)-in vitro testing","volume":"15","author":"T\u00e1trai","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib33","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bcp.15990","article-title":"Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions","volume":"90","author":"Armani","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00210-006-0042-9","article-title":"Drug transporters in pharmacokinetics","volume":"372","author":"Petzinger","year":"2006","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0968-0004(90)90032-7","article-title":"Is the glutathione S-conjugate carrier an mdr1 gene product?","volume":"15","author":"Ishikawa","year":"1990","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100023","article-title":"Organic anion transporting polypeptides: pharmacology, toxicology, structure, and transport mechanisms","volume":"77","author":"Hagenbuch","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100074","article-title":"Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail","volume":"53","author":"R\u00f6nnpagel","year":"2025","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1124\/dmd.121.000702","article-title":"Emerging roles of the human solute Carrier 22 family","volume":"50","author":"Yee","year":"2021","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib39","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1038\/s41467-023-42086-9","article-title":"Structural basis of promiscuous substrate transport by Organic cation Transporter 1","volume":"14","author":"Zeng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2026.100157_bib40","article-title":"Drug-drug interactions at organic cation Transporter 1","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100157_bib41","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.88.23.10629","article-title":"Functional expression cloning and characterization of the hepatocyte Na+\/bile acid cotransport system","volume":"88","author":"Hagenbuch","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100157_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-12-394316-3.00004-1","article-title":"The SLC10 carrier family: transport functions and molecular structure","volume":"70","author":"D\u00f6ring","year":"2012","journal-title":"Curr Top Membr"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/biomedicines10010196","article-title":"Multitasking Na+\/taurocholate cotransporting polypeptide (NTCP) as a drug target for HBV infection: from protein engineering to drug discovery","volume":"10","author":"Zakrzewicz","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib44","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41467-023-41552-8","article-title":"Structure of human drug transporters OATP1B1 and OATP1B3","volume":"14","author":"Ciut\u0103","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2026.100157_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116166","article-title":"Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition","volume":"228","author":"Marin","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib47","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.21596","article-title":"Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate","volume":"45","author":"Shin","year":"2007","journal-title":"Hepatology"},{"issue":"27","key":"10.1016\/j.pharmr.2026.100157_bib48","doi-asserted-by":"crossref","first-page":"9983","DOI":"10.1073\/pnas.1314939111","article-title":"OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin","volume":"111","author":"Chen","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib49","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1021\/acs.molpharmaceut.8b00320","article-title":"Quantification of hepatic organic anion transport proteins OAT2 and OAT7 in human liver tissue and primary hepatocytes","volume":"15","author":"Vildhede","year":"2018","journal-title":"Mol Pharm"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100157_bib50","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.3390\/cancers14194772","article-title":"Organic anion transporters (OAT) and other SLC22 transporters in progression of renal cell carcinoma","volume":"14","author":"Whisenant","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1048","article-title":"Impact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers","volume":"11","author":"Yokoyama","year":"2023","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib52","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/mol.118.114314","article-title":"Organic anion transporting polypeptides: emerging roles in cancer pharmacology","volume":"95","author":"Schulte","year":"2019","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"2-3","key":"10.1016\/j.pharmr.2026.100157_bib55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"7-8","key":"10.1016\/j.pharmr.2026.100157_bib56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17425255.2022.2113380","article-title":"The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature","volume":"18","author":"Anabtawi","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/ijms19030855","article-title":"Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions","volume":"19","author":"Alam","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100157_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107046","article-title":"Cancer-type OATP1B3-V1 is a functional plasma membrane transporter mediating increased uptake of chemotherapeutics in vitro and in vivo","volume":"209","author":"Bakos","year":"2025","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib59","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/psp4.13154","article-title":"Elucidating nonlinear pharmacokinetics of telmisartan: integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model","volume":"13","author":"Tsuchitani","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103772","article-title":"In vitro characterization of SLCO2B1 genetic variants","volume":"114","author":"Sinokki","year":"2025","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2026.100276","article-title":"Plasma coproporphyrins for evaluating OATP1B and OATP2B1 activities: coproporphyrin-III unsuitable as an OATP2B1 biomarker in Japanese general population","volume":"54","author":"Negami","year":"2026","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107492","article-title":"In vitro inhibition of organic anion transporting polypeptide 2B1 (OATP2B1) is common among marketed drugs","volume":"221","author":"Raza","year":"2026","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/pharmaceutics13010081","article-title":"Interactions of potential anti-COVID-19 compounds with multispecific ABC and OATP drug transporters","volume":"13","author":"Telbisz","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib64","doi-asserted-by":"crossref","first-page":"G550","DOI":"10.1152\/ajpgi.00364.2005","article-title":"Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep","volume":"290","author":"Mita","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.pharmr.2026.100157_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.689757","article-title":"Substrate specificities and inhibition pattern of the solute carrier Family 10 members NTCP, ASBT and SOAT","volume":"8","author":"Grosser","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/livers1040017","article-title":"Perfluoroalkyl carboxylic acids interact with the human bile acid transporter NTCP","volume":"1","author":"Ruggiero","year":"2021","journal-title":"Livers"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib67","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41467-024-46706-w","article-title":"Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15338-0","article-title":"Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP","volume":"7","author":"Donkers","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/bdd.752","article-title":"Higher clearance of Micafungin in neonates compared with adults: role of age-dependent Micafungin serum binding","volume":"32","author":"Yanni","year":"2011","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharmr.2026.100157_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2015.06.007","article-title":"Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity","volume":"120","author":"Wang","year":"2015","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib71","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.105.008748","article-title":"Inhibition of bile acid transport across Na+\/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs","volume":"34","author":"Mita","year":"2006","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib72","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1210\/en.2017-00433","article-title":"Role of the bile acid transporter SLC10A1 in liver targeting of the lipid-lowering thyroid hormone analog eprotirome","volume":"158","author":"Kersseboom","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2026.100157_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108423","article-title":"Ezetimibe protects against alpha-amanitin-induced hepatotoxicity by targeting the NTCP receptor: mechanistic insights from in vitro and in vivo models","volume":"264","author":"Xue","year":"2025","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib74","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1124\/jpet.106.102657","article-title":"Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes","volume":"318","author":"McRae","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib75","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"issue":"7-8","key":"10.1016\/j.pharmr.2026.100157_bib76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/01926233231212255","article-title":"Hepatic bile acid transporters and drug-induced hepatotoxicity","volume":"51","author":"Saran","year":"2023","journal-title":"Toxicol Pathol"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100157_bib77","doi-asserted-by":"crossref","first-page":"19342","DOI":"10.1021\/acs.jmedchem.4c01743","article-title":"Structure-activity relationships and target selectivity of phenylsulfonylamino-benzanilide inhibitors based on S1647 at the SLC10 carriers ASBT, NTCP, and SOAT","volume":"67","author":"Wannowius","year":"2024","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib79","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41594-023-01017-4","article-title":"Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2","volume":"30","author":"Suo","year":"2023","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib80","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100157_bib81","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.12998\/wjcc.v7.i23.3915","article-title":"Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver","volume":"7","author":"Li","year":"2019","journal-title":"World J Clin Cases"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib82","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/00498254.2017.1384595","article-title":"In vitro studies with two human organic anion transporters: OAT2 and OAT7","volume":"48","author":"Mathialagan","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmr.2026.100157_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107647","article-title":"Regulation of organic anion transporters: role in physiology, pathophysiology, and drug elimination","volume":"217","author":"Zhang","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib84","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/antiox13020215","article-title":"Regulation of P-glycoprotein during oxidative stress","volume":"13","author":"Shchulkin","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/membranes14110223","article-title":"The role of ABCB1, ABCG2, and SLC transporters in pharmacokinetic parameters of selected drugs and their involvement in drug-drug interactions","volume":"14","author":"Kie\u0142bowski","year":"2024","journal-title":"Membranes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib86","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/febs.15148","article-title":"P-glycoprotein: a role in the export of amyloid-beta in Alzheimer\u2019s disease?","volume":"287","author":"Chai","year":"2020","journal-title":"FEBS Journal"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib87","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/pharmrev.120.000025","article-title":"ABCB1 and ABCG2 regulation at the blood-brain barrier: potential new targets to improve brain drug delivery","volume":"75","author":"Schulz","year":"2023","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib88","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib89","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1300257","article-title":"ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder","volume":"28","author":"M\u00fcller","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/medsci3040124","article-title":"Effects of the ABCB1 (1199G > A) polymorphism on steroid sex hormone-induced P-glycoprotein expression, ATPase activity, and hormone efflux","volume":"3","author":"Peng","year":"2015","journal-title":"Med Sci (Basel)"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib91","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1111\/jcmm.13646","article-title":"Glucocorticoids modulate multidrug resistance transporters in the first trimester human placenta","volume":"22","author":"Lye","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib92","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/HJH.0000000000002150","article-title":"P-glycoprotein influences urinary excretion of aldosterone in healthy individuals","volume":"37","author":"Marques","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmr.2026.100157_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116644","article-title":"Interplay of OATP1A\/1B\/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs","volume":"175","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2026.100157_bib94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.acr.2014.10.004","article-title":"Lipid regulation of the ABCB1 and ABCG2 multidrug transporters","volume":"125","author":"Heged\u00fcs","year":"2015","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainresbull.2022.08.006","article-title":"Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters","volume":"189","author":"Dorninger","year":"2022","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharmr.2026.100157_bib96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biochi.2025.06.007","article-title":"Lipidomic analysis of MDCK-parental cells and MDCK-MDR1 cells exposed to GF120918 and clarithromycin highlights the role of P-glycoprotein in sphingolipid transport","volume":"236","author":"Decaix","year":"2025","journal-title":"Biochimie"},{"issue":"29","key":"10.1016\/j.pharmr.2026.100157_bib97","doi-asserted-by":"crossref","first-page":"21493","DOI":"10.1016\/S0021-9258(20)80566-3","article-title":"Fluorescent cellular indicators are extruded by the multidrug resistance protein","volume":"268","author":"Homolya","year":"1993","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib98","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmr.2026.100157_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fonc.2018.00428","article-title":"Interactions between ABCB1 genotype and preoperative statin use impact clinical outcomes among breast cancer patients","volume":"8","author":"Tryggvadottir","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190629","article-title":"A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions","volume":"13","author":"Szab\u00f3","year":"2018","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100157_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810599","article-title":"Selective fluorescent probes for high-throughput functional diagnostics of the human multidrug transporter P-glycoprotein (ABCB1)","volume":"23","author":"Szab\u00f3","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/17425255.2018.1416096","article-title":"ABCB1: is there a role in the drug treatment of Parkinson\u2019s disease?","volume":"14","author":"M\u00fcller","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib104","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12033-009-9220-6","article-title":"Pharmacogenetics of membrane transporters: an update on current approaches","volume":"44","author":"Sissung","year":"2010","journal-title":"Mol Biotechnol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib105","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00109-021-02105-y","article-title":"ABCB1 in dermatology: roles in skin diseases and their treatment","volume":"99","author":"Weng","year":"2021","journal-title":"J Mol Med (Berl)"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib106","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70012","article-title":"A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib","volume":"17","author":"Long","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100157_bib107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14622416.2026.2641750","article-title":"Influence of transporter polymorphisms on digoxin serum concentrations: a systematic review and meta-analysis","volume":"27","author":"Low","year":"2026","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib108","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tube.2015.04.004","article-title":"Possible association of rare polymorphism in the ABCB1 gene with rifampin and ethambutol drug-resistant tuberculosis","volume":"95","author":"Rodr\u00edguez-Castillo","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13073-016-0372-2","article-title":"Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters","volume":"8","author":"Matthaei","year":"2016","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib110","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/acs.molpharmaceut.4c00339","article-title":"Enteroids to study pediatric intestinal drug transport","volume":"21","author":"Streekstra","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.pharmr.2026.100157_bib111","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","volume":"201","author":"Cascorbi","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib112","first-page":"164","article-title":"ATP-binding cassette transporters in reproduction: a new frontier","volume":"22","author":"Bloise","year":"2016","journal-title":"Hum Reprod Update"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib113","first-page":"2460","article-title":"Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients","volume":"20","author":"G\u00f6kta\u015f","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib114","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.xphs.2017.11.021","article-title":"Active mediated transport of chloramphenicol and thiamphenicol in a Calu-3 lung epithelial cell model","volume":"107","author":"Nurbaeti","year":"2018","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cimb47030210","article-title":"ABCB1-mediated colchicine transport and its implications in familial Mediterranean fever: a systematic review","volume":"47","author":"Scuderi","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib116","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cpt.3491","article-title":"The impact of dexamethasone and prednisone on apixaban and Rivaroxaban exposure in COVID-19 patients: a physiologically based pharmacokinetic modeling study","volume":"117","author":"Terrier","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib117","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14677","article-title":"A longitudinal study of long-term renal outcome after pediatric liver transplantation in relation to CNI exposure","volume":"28","author":"Vandewiele","year":"2024","journal-title":"Pediatr Transplant"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib118","first-page":"4649","article-title":"Celecoxib enhances sensitivity to chemotherapy drugs of T-cell lymphoma","volume":"15","author":"Ma","year":"2018","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib119","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/0008-5472.CAN-06-3952","article-title":"P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines","volume":"67","author":"Fantappi\u00e8","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.110.175604","article-title":"Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp\/MDR1\/ABCB1) but not breast cancer resistance protein (BCRP\/ABCG2)","volume":"337","author":"Shen","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100157_bib121","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/pgs-2016-0113","article-title":"Pharmacogenomics and histone deacetylase inhibitors","volume":"17","author":"Goey","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib122","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3390\/ijms19071985","article-title":"Detection of the mitochondrial membrane potential by the cationic dye JC-1 in L1210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter","volume":"19","author":"Elefantova","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib123","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11095-020-2782-5","article-title":"S-(4-nitrobenzyl)-6-thioinosine (NBMPR) is not a selective inhibitor of equilibrative nucleoside transporters but also blocks efflux activity of breast cancer resistance protein","volume":"37","author":"Karbanova","year":"2020","journal-title":"Pharm Res"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib124","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.3390\/ijms23147715","article-title":"Ketoconazole reverses imatinib resistance in human chronic myelogenous leukemia K562 cells","volume":"23","author":"Prado-Carrillo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2006.10.007","article-title":"A primer on the mechanics of P-glycoprotein the multidrug transporter","volume":"55","author":"Hennessy","year":"2007","journal-title":"Pharmacol Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib126","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1128\/AAC.01421-13","article-title":"Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro","volume":"57","author":"Moss","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmr.2026.100157_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118518","article-title":"Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein","volume":"262","author":"El-Mahdy","year":"2020","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jfma.2023.02.012","article-title":"Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation","volume":"122","author":"Lin","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib129","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4161\/cbt.3.11.1176","article-title":"The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt","volume":"3","author":"Sun","year":"2004","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.leu.2404539","article-title":"The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines","volume":"21","author":"Medeiros","year":"2007","journal-title":"Leukemia"},{"issue":"2-3","key":"10.1016\/j.pharmr.2026.100157_bib131","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/bdd.699","article-title":"Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters","volume":"31","author":"Weiss","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharmr.2026.100157_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173009","article-title":"Therapeutic drugs modulate ATP-binding cassette transporter-mediated transport of amyloid beta((1-42)) in brain microvascular endothelial cells","volume":"874","author":"Shubbar","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib133","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s12276-020-0453-6","article-title":"Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo","volume":"52","author":"Yang","year":"2020","journal-title":"Exp Mol Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib134","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.exphem.2014.02.006","article-title":"Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib","volume":"42","author":"Glodkowska-Mrowka","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.pharmr.2026.100157_bib135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105436","article-title":"Glibenclamide transfer across the perfused human placenta is determined by albumin binding not transporter activity","volume":"152","author":"Lofthouse","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib137","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/biom12101360","article-title":"Antipsychotic drug fluphenazine against human cancer cells","volume":"12","author":"Duarte","year":"2022","journal-title":"Biomolecules"},{"issue":"1901","key":"10.1016\/j.pharmr.2026.100157_bib138","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2023.0074","article-title":"The roles of ABCB1\/P-glycoprotein drug transporters in regulating gut microbes and inflammation: insights from animal models, old and new","volume":"379","author":"Stoeltje","year":"2024","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib139","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/nyas.13384","article-title":"Flavonoids as modulators of metabolic enzymes and drug transporters","volume":"1398","author":"Miron","year":"2017","journal-title":"Ann N Y Acad Sci"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100157_bib140","doi-asserted-by":"crossref","first-page":"10645","DOI":"10.1021\/acsomega.0c06288","article-title":"Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo","volume":"6","author":"Qian","year":"2021","journal-title":"ACS Omega"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5155","article-title":"Mutational analysis reveals the importance of residues of the access tunnel inhibitor site to human P-glycoprotein (ABCB1)-mediated transport","volume":"33","author":"Salazar","year":"2024","journal-title":"Protein Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib142","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.3892\/ol.2017.6678","article-title":"Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer","volume":"14","author":"Chen","year":"2017","journal-title":"Oncol Lett"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411341","article-title":"Synergistic inhibitory effect of quercetin and Cyanidin-3O-Sophoroside on ABCB1","volume":"24","author":"Singh","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib144","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/pgs-2023-0204","article-title":"Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients","volume":"25","author":"Ho","year":"2024","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.pharmr.2026.100157_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123245","article-title":"The role of ABCG2 in health and disease: linking cancer therapy resistance and other disorders","volume":"360","author":"El-Ashmawy","year":"2025","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib147","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10238-022-00848-7","article-title":"Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia","volume":"23","author":"P\u00e1link\u00e1s","year":"2023","journal-title":"Clin Exp Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib148","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/ijms22062786","article-title":"Medically important alterations in transport function and trafficking of ABCG2","volume":"22","author":"Homolya","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib149","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: a perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib151","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17425255.2019.1591373","article-title":"ABCG2\/BCRP: variants, transporter interaction profile of substrates and inhibitors","volume":"15","author":"Safar","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmr.2026.100157_bib152","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of human ABCG2: from technical background to recent updates with clinical implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib153","first-page":"1339","article-title":"Mouse breast cancer resistance protein (Bcrp1\/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein","volume":"63","author":"Allen","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib154","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1593\/neo.81264","article-title":"Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2\/BCRP and ABCB1\/Pgp","volume":"11","author":"Zhang","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmr.2026.100157_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114628","article-title":"Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development","volume":"241","author":"Moinul","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib156","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","article-title":"Modulation of human BCRP (ABCG2) activity by anti-HIV drugs","volume":"59","author":"Weiss","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib157","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1124\/dmd.110.032805","article-title":"ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor","volume":"38","author":"Rajnai","year":"2010","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib158","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijantimicag.2013.01.004","article-title":"Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro","volume":"41","author":"Weiss","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib159","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.168","article-title":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo","volume":"49","author":"Yang","year":"2017","journal-title":"Exp Mol Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib160","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/00498254.2017.1397812","article-title":"Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles","volume":"48","author":"Shi","year":"2018","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib161","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138920010792927325","article-title":"Structure and function of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"11","author":"Ni","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib162","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pupt.2014.02.004","article-title":"Pharmacokinetic interaction profile of Riociguat, a new soluble guanylate cyclase stimulator, in vitro","volume":"28","author":"Rickert","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib163","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226918","article-title":"Electrochemical analysis of uric acid excretion to the intestinal lumen: effect of serum uric acid-lowering drugs and 5\/6 nephrectomy on intestinal uric acid levels","volume":"14","author":"Fujita","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib165","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.42940","article-title":"Caffeine inhibits both basal and insulin-activated urate transport","volume":"76","author":"Mandal","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.pharmr.2026.100157_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115448","article-title":"Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox","volume":"209","author":"\u00d6zvegy-Laczka","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib167","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.fpc.0000230422.50962.91","article-title":"Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics","volume":"16","author":"Niemi","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib168","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00424-006-0054-9","article-title":"Multidrug resistance-associated proteins 3, 4, and 5","volume":"453","author":"Borst","year":"2007","journal-title":"Pflugers Arch"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib169","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/dmd.113.055772","article-title":"The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia","volume":"42","author":"Keppler","year":"2014","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100157_bib170","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.1033060100","article-title":"The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs","volume":"100","author":"Reid","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib171","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/17425255.2.3.351","article-title":"Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition","volume":"2","author":"Jedlitschky","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib172","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41594-023-01176-4","article-title":"Structural basis of prostaglandin efflux by MRP4","volume":"31","author":"Pourmal","year":"2024","journal-title":"Nat Struct Mol Biol"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100157_bib173","doi-asserted-by":"crossref","first-page":"23529","DOI":"10.1074\/jbc.M303515200","article-title":"Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions","volume":"278","author":"Bodo","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib174","doi-asserted-by":"crossref","unstructured":"Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J. 997;327(1):305\u2013310. https:\/\/doi.org\/10.1042\/bj3270305","DOI":"10.1042\/bj3270305"},{"key":"10.1016\/j.pharmr.2026.100157_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105518","article-title":"Human efflux transport of testosterone, epitestosterone and other androgen glucuronides","volume":"197","author":"J\u00e4rvinen","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib176","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2)","volume":"453","author":"Nies","year":"2007","journal-title":"Pflugers Arch"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib177","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1208\/s12248-024-00950-6","article-title":"Knockout transporter cell lines to assess substrate potential towards efflux transporters","volume":"26","author":"Volpe","year":"2024","journal-title":"AAPS J"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib178","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1248\/bpb.32.2002","article-title":"Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of Taxol and saquinavir","volume":"32","author":"Roy","year":"2009","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib179","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3390\/ijms24065823","article-title":"Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis","volume":"24","author":"Vitale","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib180","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41467-024-45337-5","article-title":"Transport mechanism of human bilirubin transporter ABCC2 tuned by the inter-module regulatory domain","volume":"15","author":"Mao","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib181","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41467-024-46392-8","article-title":"Structural basis for the modulation of MRP2 activity by phosphorylation and drugs","volume":"15","author":"Mazza","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib182","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bcp.2015.03.005","article-title":"MK571 inhibits phase-2 conjugation of flavonols by Caco-2\/TC7 cells, but does not specifically inhibit their apical efflux","volume":"95","author":"Barrington","year":"2015","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib183","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/bj20021886","article-title":"Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4)","volume":"371","author":"Zelcer","year":"2003","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib184","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2003.50331","article-title":"Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane","volume":"38","author":"Rius","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib185","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.1038\/s41467-025-64490-z","article-title":"Structural basis of drug recognition by human MATE1 transporter","volume":"16","author":"Romane","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib186","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jphs.2016.03.002","article-title":"Influence of genetic polymorphisms of multidrug and toxin extrusion protein 1 on its mRNA expression in peripheral blood cells","volume":"131","author":"Ando","year":"2016","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib187","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/DMDI.2011.024","article-title":"Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents","volume":"26","author":"Grottker","year":"2011","journal-title":"Drug Metab Drug Interact"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib188","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1248\/bpb.b19-00031","article-title":"Involvement of renal efflux transporter MATE1 in renal excretion of flecainide","volume":"42","author":"Doki","year":"2019","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib189","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s40262-020-00907-w","article-title":"Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine","volume":"59","author":"Wiebe","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib190","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/pharmaceutics13050698","article-title":"A whole-body physiologically based pharmacokinetic model characterizing interplay of OCTs and MATEs in intestine, liver and kidney to predict drug-drug interactions of metformin with perpetrators","volume":"13","author":"Yang","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib191","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97160-3","article-title":"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics","volume":"11","author":"Ambrus","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib192","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1248\/bpb.b20-00753","article-title":"Involvement of human multidrug and toxic compound extrusion (MATE) transporters in testosterone transport","volume":"44","author":"Goda","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib193","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.3414","article-title":"New biomarkers for renal transporter-mediated drug-drug interactions: metabolomic effects of cimetidine, probenecid, verapamil, and rifampin in humans","volume":"117","author":"Gessner","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib194","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0030-1253224","article-title":"Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy","volume":"30","author":"Pauli-Magnus","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib195","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1038\/s41467-023-43109-1","article-title":"Structural basis of bile salt extrusion and small-molecule inhibition in human BSEP","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib196","doi-asserted-by":"crossref","first-page":"G58","DOI":"10.1152\/ajpgi.00367.2007","article-title":"Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells","volume":"294","author":"Kagawa","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib197","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2133\/dmpk.25.214","article-title":"Measurement of bile salt export pump transport activities using a fluorescent bile acid derivative","volume":"25","author":"Yamaguchi","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib198","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/dmd.114.061325","article-title":"No contribution of the ABCB11 p.444A polymorphism in Japanese patients with drug-induced cholestasis","volume":"43","author":"Kagawa","year":"2015","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib199","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000812","article-title":"iPSC-based hepatic organoids reveal a heterozygous MYO5B variant as driver of intrahepatic cholestasis","volume":"9","author":"Sgodda","year":"2025","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s11095-024-03687-1","article-title":"Conversion of olmesartan to olmesartan medoxomil, A prodrug that improves intestinal absorption, confers substrate recognition by OATP2B1","volume":"41","author":"Fukazawa","year":"2024","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib201","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/pharmaceutics16050647","article-title":"Effect of antioxidants in medicinal products on intestinal drug transporters","volume":"16","author":"Kulkarni","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100105","article-title":"OATP1B1\/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria","volume":"53","author":"Gu","year":"2025","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/psp4.12283","article-title":"Prediction of the pharmacokinetics of pravastatin as an OATP substrate using Plateable human hepatocytes with human plasma data and PBPK modeling","volume":"7","author":"Mao","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib204","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/jcph.70018","article-title":"In vitro and clinical evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-mediated drug-drug interactions of Belumosudil, a potent ROCK2 inhibitor","volume":"65","author":"Schueller","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib205","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00204-019-02417-6","article-title":"Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen","volume":"93","author":"Windt","year":"2019","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.pharmr.2026.100157_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115681","article-title":"Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma","volume":"214","author":"Asensio","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100157_bib207","article-title":"Transporters A-Z: human transporters","author":"Biotechnology","year":"2021","journal-title":"Charles River Laboratories Hungary"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib208","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.2705","article-title":"PharmVar GeneFocus: SLCO1B1","volume":"113","author":"Ramsey","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib209","first-page":"701","article-title":"STING-mediated IL-6 inhibits OATP1B1 expression via the TCF4 signaling pathway in cholestasis","volume":"12","author":"Guo","year":"2024","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib210","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib211","article-title":"SLCO1B1 polymorphisms and statin-induced myopathy","volume":"5","author":"Stewart","year":"2013","journal-title":"PLoS Curr"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib212","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00955-20","article-title":"Rifampicin transport by OATP1B1 variants","volume":"64","author":"Litjens","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib213","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jfma.2023.03.003","article-title":"SLCO1B1 and SLCO1B3 genetic mutations in Taiwanese patients with Rotor syndrome","volume":"122","author":"Cheng","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.pharmr.2026.100157_bib214","series-title":"Medical Genetics Summaries","article-title":"Simvastatin therapy and SLCO1B1 genotype","author":"Kane","year":"2012"},{"key":"10.1016\/j.pharmr.2026.100157_bib215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib216","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12325-017-0601-0","article-title":"Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in Phase 1 studies in healthy subjects","volume":"34","author":"Edwards","year":"2017","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib217","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1248\/bpb.b17-00743","article-title":"Cancer-type OATP1B3 mRNA in extracellular vesicles as a promising candidate for a serum-based colorectal cancer biomarker","volume":"41","author":"Morio","year":"2018","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib218","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000377","article-title":"Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD","volume":"8","author":"Murphy","year":"2024","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib219","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/00498254.2016.1275880","article-title":"Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3","volume":"48","author":"Sato","year":"2018","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2017.04.004","article-title":"Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings","volume":"106","author":"Yu","year":"2017","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100056","article-title":"Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions","volume":"53","author":"West","year":"2025","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"27","key":"10.1016\/j.pharmr.2026.100157_bib222","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011349","article-title":"Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: a systematic review","volume":"97","author":"Mofo Mato","year":"2018","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib223","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1159\/000491003","article-title":"OCT1-mediated metformin uptake regulates pancreatic stellate cell activity","volume":"47","author":"Wu","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100157_bib224","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.3390\/ijms23158457","article-title":"Free cholesterol affects the function and localization of human Na+\/taurocholate cotransporting polypeptide (NTCP) and organic cation Transporter 1 (OCT1)","volume":"23","author":"Idowu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/FPC.0000000000000577","article-title":"GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes","volume":"36","author":"Tourtourikov","year":"2026","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib226","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.1038\/s41467-024-51487-3","article-title":"Generation of human iPSC-derived 3D bile duct within liver organoid by incorporating human iPSC-derived blood vessel","volume":"15","author":"Carolina","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib227","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101824","article-title":"Sodium taurocholate co-transporting polypeptide deficiency","volume":"46","author":"Schneider","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib228","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12864-024-10514-9","article-title":"Population genetic admixture and evolutionary history in the Shandong Peninsula inferred from integrative modern and ancient genomic resources","volume":"25","author":"Su","year":"2024","journal-title":"BMC Genomics"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib229","article-title":"Molecular regulation of the hepatic bile acid uptake transporter and HBV entry receptor NTCP","volume":"1866","author":"Appelman","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib230","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000371565","article-title":"Progesterone metabolites as farnesoid X receptor inhibitors","volume":"33","author":"Abu-Hayyeh","year":"2015","journal-title":"Dig Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib231","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2022.03.014","article-title":"The relationship between NTCP gene varieties and the progress of liver disease after HBV infection: an updated systematic review and meta-analysis","volume":"364","author":"He","year":"2022","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib232","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jceh.2021.08.017","article-title":"A Current understanding of bile acids in chronic liver disease","volume":"12","author":"Farooqui","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib233","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jcph.1523","article-title":"Pharmacokinetic drug-drug interactions between trospium chloride and ranitidine substrates of organic cation transporters in healthy human subjects","volume":"60","author":"Abebe","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100157_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106977","article-title":"Association between G2677T\/A polymorphism in ABCB1 gene and the risk of drug resistance epilepsy: an updated systematic review and meta-analysis","volume":"185","author":"Krami","year":"2022","journal-title":"Epilepsy Res"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100157_bib235","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022113415","article-title":"Placing steroid hormones within the human ABCC3 transporter reveals a compatible amphiphilic substrate-binding pocket","volume":"42","author":"Wang","year":"2023","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib236","first-page":"93","article-title":"MDR1 gene polymorphisms and clinical relevance","volume":"33","author":"Li","year":"2006","journal-title":"Yi Chuan Xue Bao [Yi Chuan Xue Bao]"},{"key":"10.1016\/j.pharmr.2026.100157_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105740","article-title":"The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A\/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib","volume":"159","author":"Mart\u00ednez-Ch\u00e1vez","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib238","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/ph14111087","article-title":"P-glycoprotein (ABCB1\/MDR1) and BCRP (ABCG2) limit brain accumulation and cytochrome P450-3A (CYP3A) restricts oral exposure of the RET inhibitor Selpercatinib (RETEVMO)","volume":"14","author":"Wang","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmr.2026.100157_bib239","article-title":"Drug transporters ABCB1 (P-gp) and OATP, but not drug-metabolizing enzyme CYP3A4, affect the pharmacokinetics of the psychoactive alkaloid ibogaine and its metabolites","volume":"13","author":"Heydari","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib240","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12031-014-0427-z","article-title":"ABCB1 C3435T polymorphism influences the risk for Alzheimer\u2019s disease","volume":"54","author":"Feh\u00e9r","year":"2014","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmr.2026.100157_bib241","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/164_2020_418","article-title":"The blood-brain barrier in Alzheimer\u2019s disease","volume":"273","author":"Storck","year":"2022","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib242","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/0113892029280454240214072212","article-title":"Effect of Calebin-A on critical genes related to NAFLD: a protein-protein interaction network and molecular docking study","volume":"25","author":"Mahmoudi","year":"2024","journal-title":"Curr Genomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib243","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12883-017-0801-x","article-title":"Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis","volume":"17","author":"Chouchi","year":"2017","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib244","article-title":"The impact of ATP-binding cassette transporters in the diseased brain: context matters","volume":"5","author":"Baltira","year":"2024","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib245","first-page":"323","article-title":"ABCB1 3435C>T and 2677G>T\/A polymorphisms in Polish and Bosnian patients with Crohn\u2019s disease\u2014A preliminary report","volume":"17","author":"Borecki","year":"2017","journal-title":"Bosnian J Basic Med Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib246","first-page":"943","article-title":"Association of ABCB1 polymorphisms and ulcerative colitis susceptibility","volume":"8","author":"Cao","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib247","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/pgs-2018-0172","article-title":"Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis","volume":"20","author":"He","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmr.2026.100157_bib248","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.2147\/JIR.S508396","article-title":"Identification of senescence-related genes for the prediction of ulcerative colitis based on interpretable machine learning models","volume":"18","author":"Ma","year":"2025","journal-title":"J Inflam Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib249","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100157_bib250","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.3390\/ijms22136678","article-title":"The role of ABCG2 in the pathogenesis of primary hyperuricemia and gout-an update","volume":"22","author":"Eckenstaler","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib251","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260957","article-title":"Potential role of the ABCG2-Q141K polymorphism in type 2 diabetes","volume":"16","author":"Szab\u00f3","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib252","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/dmd.117.079624","article-title":"Apixaban and Rosuvas\u2014tatin pharmacokinetics in nonalcoholic fatty liver disease","volume":"46","author":"Tirona","year":"2018","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib253","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067152","article-title":"Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib254","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jhep.2015.07.016","article-title":"Canalicular membrane MRP2\/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis","volume":"63","author":"Chai","year":"2015","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib255","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/JCMA.0000000000000470","article-title":"The association of transporter ABCC2 (MRP2) genetic variation and drug-induced hyperbilirubinemia","volume":"84","author":"Huang","year":"2021","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib256","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bpg.2010.07.007","article-title":"Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)","volume":"24","author":"Strassburg","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib257","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100039","article-title":"ABCC2 p.R393W variant contributes to Dubin-Johnson syndrome by targeting MRP2 to proteasome degradation","volume":"2","author":"Sun","year":"2024","journal-title":"eGastroenterology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib258","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/508546","article-title":"Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy","volume":"194","author":"Izzedine","year":"2006","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib259","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.21037\/tlcr-23-567","article-title":"PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer","volume":"12","author":"Wang","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib260","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.2147\/OTT.S280717","article-title":"miR-424-3p contributes to the malignant progression and chemoresistance of gastric cancer","volume":"13","author":"Li","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib261","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1055\/s-0031-1281755","article-title":"Cholestasis and the role of basolateral efflux pumps","volume":"49","author":"Keppler","year":"2011","journal-title":"Z Gastroenterol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib262","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/FPC.0000000000000110","article-title":"A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome","volume":"25","author":"Dahlin","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib263","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147724","article-title":"A single-nucleotide polymorphism in ABCC4 is associated with tenofovir-related Beta2-Microglobulinuria in Thai patients with HIV-1 infection","volume":"11","author":"Likanonsakul","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib264","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1681\/ASN.0000000000000054","article-title":"Genetic and physiological effects of insulin-like growth Factor-1 (IGF-1) on human urate homeostasis","volume":"34","author":"Mandal","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib265","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1152\/ajprenal.00133.2004","article-title":"Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites","volume":"288","author":"Van Aubel","year":"2005","journal-title":"Am J Physiol Ren Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib266","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41397-021-00235-7","article-title":"ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment","volume":"21","author":"Cheli","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pharmr.2026.100157_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108722","article-title":"Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma","volume":"108","author":"Hu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib268","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/jcmm.12401","article-title":"Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis","volume":"19","author":"Muchova","year":"2015","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmr.2026.100157_bib269","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874312901812010094","article-title":"Multiple membrane transporters and some immune regulatory genes are major genetic factors to gout","volume":"12","author":"Zhu","year":"2018","journal-title":"Open Rheumatol J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1081\/DMR-200047984","article-title":"Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5)","volume":"37","author":"Ritter","year":"2005","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib271","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/cells8010039","article-title":"A human ABC transporter ABCC4 gene SNP (rs11568658, 559 G > T, G187W) reduces ABCC4-dependent drug resistance","volume":"8","author":"Tsukamoto","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib272","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.24207","article-title":"Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs","volume":"124","author":"Oevermann","year":"2009","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib273","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1389200220666190426152830","article-title":"The role of the sodium-taurocholate co-transporting polypeptide (NTCP) and bile salt export pump (BSEP) in related liver disease","volume":"20","author":"Lu","year":"2019","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib274","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102562","article-title":"Immunohistochemistry in progressive familial intrahepatic cholestasis (PFIC): bridging gap between morphology and genetics","volume":"15","author":"Nigam","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib275","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00424-006-0152-8","article-title":"The bile salt export pump","volume":"453","author":"Stieger","year":"2007","journal-title":"Pflugers Arch"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib276","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/j.gastro.2008.01.038","article-title":"Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families","volume":"134","author":"Strautnieks","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib277","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/jpc.70072","article-title":"Neonatal cholestasis: exploring genetic causes and clinical outcomes","volume":"61","author":"G\u00fcrcan Kaya","year":"2025","journal-title":"J Paediatr Child Health"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib278","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1111\/liv.14642","article-title":"ABCB11 deficiency presenting as transient neonatal cholestasis: correlation with genotypes and BSEP expression","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib279","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100840","article-title":"An ABCB11 variant registry and novel knockin mouse model of PFIC2 based on the clinically relevant ABCB11 E297G variant","volume":"66","author":"Bell","year":"2025","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib280","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.3390\/ijms26115232","article-title":"Correction of a traffic-defective missense ABCB11 variant responsible for progressive familial intrahepatic cholestasis Type 2","volume":"26","author":"Lapalus","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100157_bib281","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810758","article-title":"In vitro rescue of the bile acid transport function of ABCB11 variants by CFTR potentiators","volume":"23","author":"Mareux","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib282","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41397-018-0054-0","article-title":"Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis","volume":"18","author":"Xiang","year":"2018","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib283","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FPC.0000000000000504","article-title":"Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants","volume":"33","author":"L\u00f6nnberg","year":"2023","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib284","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cpt.701","article-title":"Genetic polymorphisms in organic cation Transporter 1 attenuates hepatic metformin exposure in humans","volume":"102","author":"Sundelin","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib285","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/bcp.14591","article-title":"Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: a large prospective trial","volume":"87","author":"Kuhlmann","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib286","doi-asserted-by":"crossref","DOI":"10.2174\/1573399820666230807145202","article-title":"Influence of solute carrier Family 22 Member 1 (SLC22A1) gene polymorphism on metformin pharmacokinetics and HbA1c levels: a systematic review","volume":"20","author":"Pradana","year":"2024","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib287","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2002907","article-title":"Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content","volume":"16","author":"Liang","year":"2018","journal-title":"PLoS Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib288","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/metabo11020075","article-title":"Evaluation of pharmacokinetic drug-drug interactions: a review of the mechanisms, in vitro and in silico approaches","volume":"11","author":"Peng","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmr.2026.100157_bib289","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2407-12-109","article-title":"Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance","volume":"12","author":"Heise","year":"2012","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib290","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/molpharm.122.000539","article-title":"Cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3) is localized in lysosomes and mediates resistance against kinase inhibitors","volume":"102","author":"Haberkorn","year":"2022","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib291","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02977789","article-title":"Induction of phase I, II and III drug metabolism\/transport by xenobiotics","volume":"28","author":"Xu","year":"2005","journal-title":"Arch Pharm Res"},{"issue":"51","key":"10.1016\/j.pharmr.2026.100157_bib292","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046431","article-title":"ABCB1 rs2032582 variant is potentially linked withScutellariae Radix-induced liver injury: a case report","volume":"104","author":"Tang","year":"2025","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib293","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib294","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01.fpc.0000239969.46594.d0","article-title":"MDR1 genotype-dependent regulation of the aldosterone system in humans","volume":"17","author":"Zolk","year":"2007","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib295","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol Rev"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib296","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib297","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.103.062091","article-title":"Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3","volume":"309","author":"Chu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib298","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114346","article-title":"Targeting breast cancer resistance protein (BCRP\/ABCG2): functional inhibitors and expression modulators","volume":"237","author":"Zattoni","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib299","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1038\/s41467-024-49204-1","article-title":"Inhibition and transport mechanisms of the ABC transporter hMRP5","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib300","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.21037\/tcr-24-1129","article-title":"Targeting breast cancer resistance protein (BCRP\/ABCG2) in cancer","volume":"13","author":"Chen","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib301","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.prostaglandins.2013.08.002","article-title":"Contribution of multidrug resistance-associated proteins (MRPs) to the release of prostanoids from A549 cells","volume":"106","author":"Furugen","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib302","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1590\/S0100-879X2008000900005","article-title":"ABCB1 C1236T, G2677T\/A and C3435T polymorphisms in systemic lupus erythematosus patients","volume":"41","author":"Gonzalez","year":"2008","journal-title":"Braz J Med Biol Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib303","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s12012-025-10056-w","article-title":"Association between ABCG2 polymorphism and statin-induced adverse events: a meta-analysis","volume":"25","author":"Lee","year":"2025","journal-title":"Cardiovasc Toxicol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib304","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1096\/fasebj.11.7.9212074","article-title":"Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP\/cMOAT) gene in liver","volume":"11","author":"Keppler","year":"1997","journal-title":"FASEB J"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100157_bib305","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.3390\/ijms26178652","article-title":"Frequency of polymorphisms in SLC47A1 (rs2252281 and rs2289669) and SLC47A2 (rs34834489 and rs12943590) and the influence of SLC22A1 (rs72552763 and rs622342) on HbA1c levels in Mexican-mestizo patients with DMT2 treated with metformin monotherapy","volume":"26","author":"G\u00f3mez-Hern\u00e1ndez","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib306","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13023-025-03599-2","article-title":"Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review","volume":"20","author":"Vitale","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib307","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/dme.13351","article-title":"Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed type 2 diabetes","volume":"34","author":"Liang","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.pharmr.2026.100157_bib308","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1423214","article-title":"Integration of genomics, clinical characteristics and baseline biological profiles to predict the risk of liver injury induced by high-dose methotrexate","volume":"15","author":"Lin","year":"2024","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib309","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000083","article-title":"Identification of epigenetic methylation signatures with clinical value in Crohn\u2019s disease","volume":"10","author":"Moret-Tatay","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.pharmr.2026.100157_bib310","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114735","article-title":"Regulation of P-glycoprotein through CaMKII\/cPLA2 pathway in lymphocytes for treating refractory rheumatoid arthritis by manidipine","volume":"156","author":"Yan","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib311","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1517\/17425255.2015.1053462","article-title":"Nature and uses of fluorescent dyes for drug transporter studies","volume":"11","author":"Fardel","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib312","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejps.2011.05.002","article-title":"Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes","volume":"43","author":"De Bruyn","year":"2011","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib313","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acs.molpharmaceut.5b00763","article-title":"Downregulation of organic anion transporting polypeptide (OATP) 1B1 transport function by lysosomotropic drug chloroquine: implication in OATP-mediated drug-drug interactions","volume":"13","author":"Alam","year":"2016","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib314","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/dmd.119.088898","article-title":"Mechanistic modeling of the hepatic disposition of Estradiol-17beta-Glucuronide in sandwich-cultured human hepatocytes","volume":"48","author":"Ito","year":"2020","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib315","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1124\/dmd.114.056945","article-title":"Novel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation","volume":"42","author":"Powell","year":"2014","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib316","first-page":"G12","article-title":"Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration","volume":"277","author":"Liu","year":"1999","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib317","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0741-5214(91)90319-P","article-title":"Randomized clinical trials and the Society for Vascular Surgery","volume":"13","author":"Clagett","year":"1991","journal-title":"J Vasc Surg"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib318","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/toxsci\/kfp033","article-title":"Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714","volume":"108","author":"Feng","year":"2009","journal-title":"Toxicol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib319","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/jps.23933","article-title":"Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition","volume":"103","author":"De Bruyn","year":"2014","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib320","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/dmd.117.079277","article-title":"Intravital multiphoton microscopy with fluorescent bile salts in rats as an in vivo biomarker for hepatobiliary transport inhibition","volume":"46","author":"Ryan","year":"2018","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib321","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1124\/dmd.107.019398","article-title":"Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors","volume":"36","author":"Ye","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib322","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.105.004481","article-title":"Canalicular and sinusoidal disposition of bilirubin mono- and diglucuronides in sandwich-cultured human and rat primary hepatocytes","volume":"33","author":"Lengyel","year":"2005","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib323","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1872-034X.2007.00255.x","article-title":"Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes","volume":"38","author":"Lengyel","year":"2008","journal-title":"Hepatol Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100157_bib324","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2008.06.008","article-title":"Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human","volume":"35","author":"Li","year":"2008","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib325","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1124\/dmd.104.001669","article-title":"Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes","volume":"33","author":"Annaert","year":"2005","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib326","first-page":"1277","article-title":"P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes","volume":"29","author":"Annaert","year":"2001","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib327","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.dmpk.2018.04.001","article-title":"Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes","volume":"33","author":"Kanda","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib328","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tiv.2008.11.001","article-title":"Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes","volume":"23","author":"Treijtel","year":"2009","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib329","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.tiv.2009.10.009","article-title":"Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes","volume":"24","author":"Jemnitz","year":"2010","journal-title":"Toxicol In Vitro"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib330","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12248-020-00496-3","article-title":"Pitfalls in predicting hepatobiliary drug transport using human sandwich-cultured hepatocytes","volume":"22","author":"Kumar","year":"2020","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib331","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-phenotyping\u201d using primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib332","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1124\/dmd.115.067629","article-title":"Hepatocellular disposition and transporter interactions with Tolvaptan and metabolites in sandwich-cultured human hepatocytes","volume":"44","author":"Lu","year":"2016","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib333","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1007\/s11095-009-9909-z","article-title":"Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function","volume":"26","author":"Swift","year":"2009","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib334","doi-asserted-by":"crossref","first-page":"567","DOI":"10.18433\/jpps30706","article-title":"Probe cocktail to assess transporter function in sandwich-cultured human hepatocytes","volume":"22","author":"Guo","year":"2019","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib335","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.120.000057","article-title":"Function and expression of bile salt export pump in suspension human hepatocytes","volume":"49","author":"Chothe","year":"2021","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib336","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.xphs.2020.10.041","article-title":"Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: comparison with isolated suspended hepatocytes","volume":"110","author":"Yoshikado","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmr.2026.100157_bib337","first-page":"2025","article-title":"A 3D in vitro model of the human hepatobiliary junction","author":"Westerfield","year":"2025","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib338","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.3390\/ijms22095038","article-title":"In vitro liver toxicity testing of chemicals: a pragmatic approach","volume":"22","author":"Tabernilla","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib339","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/03602530903491881","article-title":"Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity","volume":"42","author":"Swift","year":"2010","journal-title":"Drug Metab Rev"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib340","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cpt.1112","article-title":"Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance","volume":"104","author":"Zamek-Gliszczynski","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib341","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.06.015","article-title":"Multidrug resistance-associated protein 4 in pharmacology: overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics","volume":"231","author":"Berthier","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmr.2026.100157_bib342","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100325","article-title":"Effect of bile acids on the expression of MRP3 and MRP4: an in vitro study in HepG2 cell line","volume":"24","author":"P\u00e9rez-Pineda","year":"2021","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib343","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1055\/a-1481-2663","article-title":"Role of membrane lipid rafts in MRP4 (ABCC4) dependent regulation of the cAMP pathway in blood platelets","volume":"121","author":"Belleville-Rolland","year":"2021","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib344","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/cpt.2605","article-title":"Regulation of drug transport proteins-from mechanisms to clinical impact: a white paper on behalf of the international transporter consortium","volume":"112","author":"Brouwer","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib345","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1124\/dmd.105.003988","article-title":"Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways","volume":"33","author":"Cheng","year":"2005","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib346","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.121.000704","article-title":"Transcriptional regulation of solute carrier (SLC) drug transporters","volume":"50","author":"Zhou","year":"2022","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib347","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbamcr.2006.04.014","article-title":"Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration","volume":"1773","author":"Geier","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmr.2026.100157_bib348","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fphar.2016.00111","article-title":"Rifampin regulation of drug transporters gene expression and the association of microRNAs in human hepatocytes","volume":"7","author":"Benson","year":"2016","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib349","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/liv.14212","article-title":"microRNA-206 modulates the hepatic expression of the organic anion-transporting polypeptide 1B1","volume":"39","author":"El Saadany","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib350","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90143-4","article-title":"Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p","volume":"11","author":"Barbier","year":"2021","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib351","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1021\/acs.molpharmaceut.0c00193","article-title":"Regulation of organic anion transporting Polypeptide 2B1 expression by microRNA in the human liver","volume":"17","author":"Tajiri","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.pharmr.2026.100157_bib352","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.06.013","article-title":"Post-translational modifications of transporters","volume":"192","author":"Czuba","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib353","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052563","article-title":"N-Glycosylation dictates proper processing of organic anion transporting polypeptide 1B1","volume":"7","author":"Yao","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib354","article-title":"Human organic anion transporting polypeptide 1B3 (OATP1B3) is more heavily N-glycosylated than OATP1B1 in extracellular loops 2 and 5","volume":"278","author":"Liang","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib355","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/acsptsci.3c00076","article-title":"Importance of N-glycosylation for the expression and function of human organic anion transporting Polypeptide 2B1","volume":"6","author":"Li","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib356","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100157_bib357","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-21-0023","article-title":"Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation","volume":"27","author":"Hayden","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100157_bib358","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1074\/jbc.M109.056457","article-title":"Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated internalization","volume":"285","author":"K\u00f6ck","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib359","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2024.100007","article-title":"Regulation of organic anion transporting polypeptide 1B1 transport function by concurrent phosphorylation and lysine-acetylation: a novel posttranslational regulation mechanism","volume":"107","author":"Tambe","year":"2025","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/pharmaceutics16010063","article-title":"Assessing trans-inhibition of OATP1B1 and OATP1B3 by calcineurin and\/or PPIase inhibitors and global identification of OATP1B1\/3-associated proteins","volume":"16","author":"Powell","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib361","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183554","article-title":"Leucine heptad motifs within transmembrane domains affect function and oligomerization of human organic anion transporting polypeptide 1B1","volume":"1863","author":"Ni","year":"2021","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib362","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1124\/dmd.123.001248","article-title":"Interaction of human OATP1B1 with PDZK1 is required for its trafficking to the hepatocyte plasma membrane","volume":"51","author":"Wang","year":"2023","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib363","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/dmd.119.089847","article-title":"OATP1B3 expression and function is modulated by Coexpression with OCT1, OATP1B1, and NTCP","volume":"48","author":"Zhang","year":"2020","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib364","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/cpt.1073","article-title":"Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: Establishing induction relationships using ascending dose rifampin","volume":"104","author":"Lutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100157_bib365","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.3748\/wjg.14.7068","article-title":"Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents","volume":"14","author":"Mottino","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"4-5","key":"10.1016\/j.pharmr.2026.100157_bib366","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejps.2008.01.008","article-title":"Coordinated induction of drug transporters and phase I and II metabolism in human liver slices","volume":"33","author":"Olinga","year":"2008","journal-title":"Eur J Pharm Sci"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100157_bib367","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.1074\/jbc.M010173200","article-title":"Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin","volume":"276","author":"Geick","year":"2001","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib368","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.bcp.2012.01.030","article-title":"Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters","volume":"83","author":"Chen","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100157_bib369","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.684156","article-title":"Rifampicin induces gene, protein, and activity of P-glycoprotein (ABCB1) in human precision-cut intestinal slices","volume":"12","author":"Martinec","year":"2021","journal-title":"Front Pharmacol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib370","doi-asserted-by":"crossref","first-page":"13213","DOI":"10.1074\/jbc.M414646200","article-title":"Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain","volume":"280","author":"Johnson","year":"2005","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100157_bib371","doi-asserted-by":"crossref","first-page":"11037","DOI":"10.1073\/pnas.94.20.11037","article-title":"p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents","volume":"94","author":"Thottassery","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib372","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1074\/jbc.275.4.2979","article-title":"Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1","volume":"275","author":"Hu","year":"2000","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib373","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1053\/jhep.2001.24667","article-title":"Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling","volume":"33","author":"Ros","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib374","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/nar\/gkac133","article-title":"Molecular basis of crosstalk in nuclear receptors: heterodimerization between PXR and CAR and the implication in gene regulation","volume":"50","author":"Bwayi","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib375","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1194\/jlr.M700417-JLR200","article-title":"Liver receptor homolog 1 transcriptionally regulates human bile salt export pump expression","volume":"49","author":"Song","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib376","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fphar.2016.00456","article-title":"Pregnane X receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via Coactivator interactions","volume":"7","author":"Pavek","year":"2016","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib377","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1471-4159.2008.05537.x","article-title":"Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells","volume":"106","author":"Lim","year":"2008","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib378","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0026-895X(24)12293-6","article-title":"Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway","volume":"60","author":"Yang","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100157_bib379","doi-asserted-by":"crossref","first-page":"15174","DOI":"10.1074\/jbc.272.24.15174","article-title":"NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells","volume":"272","author":"Zhou","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib380","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1665-2681(19)32119-2","article-title":"Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2","volume":"3","author":"Catania","year":"2004","journal-title":"Ann Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib381","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.abb.2004.09.019","article-title":"Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism","volume":"433","author":"Eloranta","year":"2005","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmr.2026.100157_bib382","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1486783","article-title":"MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters","volume":"15","author":"Lu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib383","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","article-title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin","volume":"7","author":"Kovalchuk","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib384","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2017.08.027","article-title":"The miR-491-3p\/Sp3\/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma","volume":"408","author":"Zhao","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmr.2026.100157_bib385","article-title":"Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib386","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12251","article-title":"MicroRNAs and their relevance to ABC transporters","volume":"77","author":"Haenisch","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib387","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.cellsig.2013.08.032","article-title":"MiR-27a modulates the MDR1\/P-glycoprotein expression by inhibiting FZD7\/beta-catenin pathway in hepatocellular carcinoma cells","volume":"25","author":"Chen","year":"2013","journal-title":"Cell Signal"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib388","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbamcr.2007.03.023","article-title":"The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein","volume":"1773","author":"Fu","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib389","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ijc.25310","article-title":"Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells","volume":"128","author":"Ferr\u00e1ndiz-Huertas","year":"2011","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib390","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/mol.109.061713","article-title":"Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression","volume":"78","author":"Xie","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100157_bib391","doi-asserted-by":"crossref","first-page":"23812","DOI":"10.1074\/jbc.M604890200","article-title":"Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells","volume":"281","author":"Szatmari","year":"2006","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib392","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17425255.2020.1732348","article-title":"Transcription factor-mediated regulation of the BCRP\/ABCG2 efflux transporter: a review across tissues and species","volume":"16","author":"Gorczyca","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib393","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib394","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbrc.2010.12.074","article-title":"Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1","volume":"404","author":"Sugiyama","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100157_bib395","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1128\/MCB.00331-08","article-title":"Regulation of ABCG2 expression at the 3\u2032 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line","volume":"28","author":"To","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib396","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1124\/mol.108.054163","article-title":"MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP\/ABCG2) in human cancer cells","volume":"75","author":"Pan","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib397","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bcp.2010.12.018","article-title":"Breast cancer resistance protein BCRP\/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and \u2212520h) and their differential expression in stem-like ABCG2+ cancer cells","volume":"81","author":"Li","year":"2011","journal-title":"Biochem Pharmacol"},{"issue":"54","key":"10.1016\/j.pharmr.2026.100157_bib398","doi-asserted-by":"crossref","first-page":"92018","DOI":"10.18632\/oncotarget.21272","article-title":"MicroRNA-212\/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells","volume":"8","author":"Kaehler","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib399","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/dmd.115.067470","article-title":"MicroRNA Pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy","volume":"44","author":"Yu","year":"2016","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113865","article-title":"Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells","volume":"175","author":"Kovacsics","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib401","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1124\/dmd.121.000450","article-title":"Role and regulation of hepatobiliary ATP-binding cassette transporters during chemical-induced liver injury","volume":"50","author":"Ghanem","year":"2022","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib402","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib403","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hep.23625","article-title":"Regulation of multidrug resistance-associated protein 2 by calcium signaling in mouse liver","volume":"52","author":"Cruz","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib404","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/jhep.2001.26213","article-title":"Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver","volume":"34","author":"Donner","year":"2001","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib405","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/bjc.2012.88","article-title":"MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer","volume":"106","author":"Xu","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmr.2026.100157_bib406","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113795","article-title":"Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis","volume":"174","author":"Zeng","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib407","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bcp.2013.10.017","article-title":"ABCC4 is regulated by microRNA-124a and microRNA-506","volume":"87","author":"Markova","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib408","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.3390\/ijms21145157","article-title":"Rapid regulation of human multidrug and extrusion transporters hMATE1 and hMATE2K","volume":"21","author":"Kantauskait\u0117","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib409","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1534-5807(03)00131-X","article-title":"Nuclear receptors orchestrate detoxification pathways","volume":"4","author":"Roy-Chowdhury","year":"2003","journal-title":"Dev Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib410","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1124\/mol.62.3.638","article-title":"Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification","volume":"62","author":"Maglich","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib411","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1074\/jbc.M109326200","article-title":"Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor","volume":"277","author":"Kast","year":"2002","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib412","first-page":"1467","article-title":"Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor","volume":"29","author":"Staudinger","year":"2001","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.pharmr.2026.100157_bib413","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0076-6879(05)00028-5","article-title":"Coordinate transcriptional regulation of transport and metabolism","volume":"400","author":"Eloranta","year":"2005","journal-title":"Methods Enzymol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib414","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1124\/pr.55.4.2","article-title":"Induction of drug metabolism: the role of nuclear receptors","volume":"55","author":"Handschin","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib415","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib416","first-page":"1135","article-title":"Genomics versus orphan nuclear receptors\u2014a half-time report","volume":"16","author":"Willson","year":"2002","journal-title":"Mol Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib417","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1389200054633826","article-title":"Regulation of hepatic transporters by xenobiotic receptors","volume":"6","author":"Klaassen","year":"2005","journal-title":"Curr Drug Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib418","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/me.2002-0421","article-title":"Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor","volume":"17","author":"Rosenfeld","year":"2003","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib419","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/abbi.1999.1351","article-title":"P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR","volume":"369","author":"Waxman","year":"1999","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib420","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1440-1746.2009.05800.x","article-title":"Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease","volume":"24","author":"Congiu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib421","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1124\/dmd.112.045112","article-title":"Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null mice","volume":"40","author":"Aleksunes","year":"2012","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib422","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/ijms19010261","article-title":"The role of miRNAs in the pathophysiology of liver diseases and toxicity","volume":"19","author":"Schueller","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib423","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","article-title":"MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases","volume":"70","author":"Wang","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib425","article-title":"Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: a comprehensive mechanistic review","volume":"1870","author":"Laddha","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib426","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-022-00802-8","article-title":"Hepatic transporters alternations associated with non-alcoholic fatty liver disease (NAFLD): a systematic review","volume":"48","author":"Omidkhoda","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib427","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.23","article-title":"Drug-induced liver injury: the role of drug metabolism and transport","volume":"53","author":"Corsini","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib428","article-title":"Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications","volume":"12","author":"Hu","year":"2025","journal-title":"Genes Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib429","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2022.09.001","article-title":"Loss of liver function in chronic liver disease: an identity crisis","volume":"78","author":"Berasain","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib430","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00134-008-1358-3","article-title":"A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis","volume":"35","author":"Kruger","year":"2009","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib431","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/dmd.107.016907","article-title":"Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta","volume":"36","author":"Le Vee","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib432","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6","volume":"37","author":"Le Vee","year":"2009","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib433","article-title":"Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy","volume":"2013","author":"Buxhofer-Ausch","year":"2013","journal-title":"J Drug Deliv"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib434","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/jpet.123.002019","article-title":"Dysregulation of human hepatic drug transporters by proinflammatory cytokines","volume":"391","author":"Hao","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib435","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/03602530601093489","article-title":"Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies","volume":"39","author":"Hewitt","year":"2007","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib436","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.110.035873","article-title":"Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes","volume":"39","author":"Guo","year":"2011","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib437","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/lt.22099","article-title":"Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model","volume":"16","author":"Kawahara","year":"2010","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib438","first-page":"1","article-title":"Hepatocyte cryopreservation: is it time to change the strategy?","volume":"16","author":"St\u00e9phenne","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib439","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.105.009118","article-title":"Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport","volume":"34","author":"Bi","year":"2006","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"5-6","key":"10.1016\/j.pharmr.2026.100157_bib440","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0887-2333(03)00102-4","article-title":"Isolated human hepatocytes in culture display markedly different gene expression patterns depending on attachment status","volume":"17","author":"Waring","year":"2003","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib441","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","article-title":"Near completely humanized liver in mice shows human-type metabolic responses to drugs","volume":"165","author":"Tateno","year":"2004","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib442","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib443","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nbt1326","article-title":"Robust expansion of human hepatocytes in Fah\u2212\/\u2212\/Rag2\u2212\/\u2212\/Il2rg\u2212\/\u2212 mice","volume":"25","author":"Azuma","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib444","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2011.01.042","article-title":"The reconstituted \u201chumanized liver\u201d in TK-NOG mice is mature and functional","volume":"405","author":"Hasegawa","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237809","article-title":"Culture density contributes to hepatic functions of fresh human hepatocytes isolated from chimeric mice with humanized livers: novel, long-term, functional two-dimensional in vitro tool for developing new drugs","volume":"15","author":"Yamasaki","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib446","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3109\/00498254.2012.675093","article-title":"Generation of proliferating human hepatocytes using Upcyte(R) technology: characterisation and applications in induction and cytotoxicity assays","volume":"42","author":"Burkard","year":"2012","journal-title":"Xenobiotica"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100157_bib447","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mrgentox.2013.09.008","article-title":"Optimization of upcyte\u00ae human hepatocytes for the in vitro micronucleus assay","volume":"758","author":"N\u00f6renberg","year":"2013","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib448","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.117.078238","article-title":"Quantitative expression of hepatobiliary transporters and functional uptake of substrates in hepatic two-dimensional sandwich cultures: a comparative evaluation of upcyte and primary human hepatocytes","volume":"46","author":"Schaefer","year":"2018","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib449","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.stem.2018.10.018","article-title":"In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity","volume":"23","author":"Zhang","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib450","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/dmd.120.000275","article-title":"Functional proliferating human hepatocytes: in vitro hepatocyte model for drug metabolism, excretion, and toxicity","volume":"49","author":"Qiao","year":"2021","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib451","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1038\/s41596-025-01211-2","article-title":"Expansion of human hepatocytes and their application in three-dimensional culture and genetic manipulation","volume":"20","author":"Zhang","year":"2025","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib452","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1039\/C2TX20051A","article-title":"In vitro models for liver toxicity testing","volume":"2","author":"Soldatow","year":"2013","journal-title":"Toxicol Res"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100157_bib453","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1177\/1535370216657448","article-title":"Cell sources for in vitro human liver cell culture models","volume":"241","author":"Zeilinger","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib454","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/hep.28780","article-title":"Massive rearrangements of cellular microRNA signatures are key drivers of hepatocyte dedifferentiation","volume":"64","author":"Lauschke","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib455","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.3390\/ijms20122910","article-title":"Dedifferentiation of primary hepatocytes is accompanied with reorganization of lipid metabolism indicated by altered molecular lipid and miRNA profiles","volume":"20","author":"Kiamehr","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100157_bib456","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-4939-9420-5_21","article-title":"Establishment of sandwich cultures of primary human hepatocytes","volume":"1981","author":"Gijbels","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib457","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2131\/jts.48.251","article-title":"Construction of extended and functional bile canaliculi using long-term sandwich-cultured cryopreserved human hepatocytes and the application of hepatocytes for predicting the biliary excretion of pharmaceutical and food-related compounds","volume":"48","author":"Kitaguchi","year":"2023","journal-title":"J Toxicol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib458","first-page":"35","article-title":"Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion","volume":"24","author":"Ullrich","year":"2007","journal-title":"ALTEX"},{"key":"10.1016\/j.pharmr.2026.100157_bib459","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152662","article-title":"Physiologically inspired culture medium prolongs the lifetime and insulin sensitivity of human hepatocytes in micropatterned co-cultures","volume":"449","author":"Davidson","year":"2021","journal-title":"Toxicology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib460","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00204-013-1078-5","article-title":"Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME","volume":"87","author":"Godoy","year":"2013","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib461","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/dmd.118.084988","article-title":"A comparison of total and plasma membrane abundance of transporters in suspended, plated, sandwich-cultured human hepatocytes versus human liver tissue using quantitative targeted proteomics and cell surface biotinylation","volume":"47","author":"Kumar","year":"2019","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib462","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/mp900044x","article-title":"Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes","volume":"6","author":"Li","year":"2009","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib463","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tiv.2017.03.012","article-title":"Architecture in 3D cell culture: an essential feature for in vitro toxicology","volume":"45","author":"Leli\u00e8vre","year":"2017","journal-title":"Toxicol In Vitro"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib464","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00204-019-02437-2","article-title":"Mechanisms and in vitro models of drug-induced cholestasis","volume":"93","author":"Gijbels","year":"2019","journal-title":"Arch Toxicol"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100157_bib465","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910214","article-title":"Three-dimensional liver culture systems to maintain primary hepatic properties for toxicological analysis in vitro","volume":"22","author":"Kammerer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100157_bib466","article-title":"Advanced 3D liver models for in vitro genotoxicity testing following long-term nanomaterial exposure","volume":"160","author":"Llewellyn","year":"2020","journal-title":"J Vis Exp"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib467","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.chemrestox.1c00227","article-title":"Evaluation of a three-dimensional primary human hepatocyte spheroid model: adoption and industrialization for the enhanced detection of drug-induced liver injury","volume":"34","author":"Schofield","year":"2021","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib468","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tiv.2006.11.004","article-title":"Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity","volume":"21","author":"Baudoin","year":"2007","journal-title":"Toxicol In Vitro"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib469","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/cpt.2887","article-title":"3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction","volume":"113","author":"J\u00e4rvinen","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100157_bib470","doi-asserted-by":"crossref","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100157_bib471","doi-asserted-by":"crossref","DOI":"10.1038\/srep35434","article-title":"Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability","volume":"6","author":"Hendriks","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100157_bib472","series-title":"Understanding the transport mechanisms of BSEP to improve the prediction of DILI compounds","author":"Kruijf","year":"2020"},{"issue":"8065","key":"10.1016\/j.pharmr.2026.100157_bib473","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41586-025-08861-y","article-title":"Generation of human adult hepatocyte organoids with metabolic functions","volume":"641","author":"Igarashi","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib474","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep.24760","article-title":"Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing","volume":"55","author":"Tost\u00f5es","year":"2012","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100157_bib475","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","article-title":"Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury","volume":"91","author":"Proctor","year":"2017","journal-title":"Arch Toxicol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib476","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.xphs.2020.02.021","article-title":"Three-dimensional spheroids with primary human liver cells and differential roles of Kupffer cells in drug-induced liver injury","volume":"109","author":"Li","year":"2020","journal-title":"J Pharm Sci"},{"issue":"4455","key":"10.1016\/j.pharmr.2026.100157_bib477","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.6248960","article-title":"Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen","volume":"209","author":"Knowles","year":"1980","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib478","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 is a hepatoblastoma-derived cell line","volume":"40","author":"L\u00f3pez-Terrada","year":"2009","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib479","first-page":"3858","article-title":"Growth of human hepatoma cells lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100157_bib480","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib481","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2004.01.002","article-title":"Origin and characterization of a human bipotent liver progenitor cell line","volume":"126","author":"Parent","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib482","first-page":"1083","article-title":"A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies","volume":"88","author":"Ramaiahgari","year":"2014","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib483","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1039\/C6TX00101G","article-title":"Characterization of a functional C3A liver spheroid model","volume":"5","author":"Gaskell","year":"2016","journal-title":"Toxicol Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib484","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1007\/s00204-019-02576-6","article-title":"Development of in vitro 3D cell model from hepatocellular carcinoma (HepG2) cell line and its application for genotoxicity testing","volume":"93","author":"\u0160tampar","year":"2019","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib485","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.dmpk.2018.03.003","article-title":"Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: focusing on drug-metabolizing enzymes","volume":"33","author":"Shi","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pharmr.2026.100157_bib486","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111046","article-title":"Cyanotoxin cylindrospermopsin disrupts lipid homeostasis and metabolism in a 3D in vitro model of the human liver","volume":"397","author":"Chowdhury","year":"2024","journal-title":"Chem-Biol Interact"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib487","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118123","article-title":"Modulation of Huh7.5 spheroid formation and functionality using modified PEG-based hydrogels of different stiffness","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100157_bib488","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1743-422X-6-103","article-title":"Three-dimensional Huh7 cell culture system for the study of hepatitis C virus infection","volume":"6","author":"Sainz","year":"2009","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib489","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18174-z","article-title":"A novel differentiated HuH-7 cell model to examine bile acid metabolism, transport and cholestatic hepatotoxicity","volume":"12","author":"Saran","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100157_bib490","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejps.2019.01.022","article-title":"Protein expression and function of organic anion transporters in short-term and long-term cultures of Huh7 human hepatoma cells","volume":"130","author":"Malinen","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib491","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s00204-019-02552-0","article-title":"High-throughput confocal imaging of differentiated 3D liver-like spheroid cellular stress response reporters for identification of drug-induced liver injury liability","volume":"93","author":"Hiemstra","year":"2019","journal-title":"Arch Toxicol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib492","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem-Biol Interact"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib493","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1124\/dmd.116.069831","article-title":"Contextualizing hepatocyte functionality of cryopreserved HepaRG cell cultures","volume":"44","author":"Jackson","year":"2016","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib494","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.26160","article-title":"Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells","volume":"57","author":"Anth\u00e9rieu","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib495","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.tiv.2013.07.003","article-title":"Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells","volume":"27","author":"Le Vee","year":"2013","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib496","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34421-8","article-title":"Functional polarization of human hepatoma HepaRG cells in response to forskolin","volume":"8","author":"Mayati","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib497","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1021\/mp300171p","article-title":"Expression and transport function of drug uptake transporters in differentiated HepaRG cells","volume":"9","author":"Kotani","year":"2012","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib498","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acs.molpharmaceut.5b00659","article-title":"Disruption of BSEP function in HepaRG cells alters bile acid disposition and is a susceptive factor to drug-induced cholestatic injury","volume":"13","author":"Qiu","year":"2016","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib499","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jcmgh.2020.09.016","article-title":"Controversies surrounding the origin of hepatocytes in adult livers and the in vitro generation or propagation of hepatocytes","volume":"11","author":"Pek","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib500","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.113.054528","article-title":"Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition","volume":"42","author":"Lundquist","year":"2014","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib501","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s42003-022-04046-9","article-title":"A comprehensive transcriptomic comparison of hepatocyte model systems improves selection of models for experimental use","volume":"5","author":"Ardisasmita","year":"2022","journal-title":"Commun Biol"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100157_bib502","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1089\/scd.2016.0099","article-title":"Prediction of differentiation tendency toward hepatocytes from gene expression in undifferentiated human pluripotent stem cells","volume":"25","author":"Yanagihara","year":"2016","journal-title":"Stem Cells Dev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib503","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2017.02.005","article-title":"Derivation of pluripotent stem cells with in vivo embryonic and extraembryonic potency","volume":"169","author":"Yang","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib504","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41422-020-0293-x","article-title":"Generation of human hepatocytes from extended pluripotent stem cells","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib505","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/mt.2011.234","article-title":"Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction","volume":"20","author":"Takayama","year":"2012","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib506","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jhep.2012.04.038","article-title":"Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1alpha transduction","volume":"57","author":"Takayama","year":"2012","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib507","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1089\/scd.2019.0064","article-title":"Guide to the assessment of mature liver gene expression in stem cell-derived hepatocytes","volume":"28","author":"Zabulica","year":"2019","journal-title":"Stem Cells Dev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib508","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/ijms21020469","article-title":"Characterization of human induced pluripotent stem cell-derived hepatocytes with mature features and potential for modeling metabolic diseases","volume":"21","author":"Holmgren","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib509","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bcp.2013.06.029","article-title":"Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells","volume":"86","author":"Ulvestad","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100157_bib510","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bcp.2018.06.026","article-title":"Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines","volume":"155","author":"Kvist","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib511","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70390","article-title":"Standard protocols for characterising primary and in vitro-generated human hepatocytes","volume":"29","author":"Heydari","year":"2025","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib512","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000702","article-title":"Enhancement of hepatic differentiation from induced pluripotent stem cells by suppressing epithelial-mesenchymal transition","volume":"9","author":"Li","year":"2025","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib513","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3892\/br.2015.480","article-title":"Polarisation and functional characterisation of hepatocytes derived from human embryonic and mesenchymal stem cells","volume":"3","author":"Palakkan","year":"2015","journal-title":"Biomed Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib514","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/s41467-020-15337-2","article-title":"Stem cell-derived polarized hepatocytes","volume":"11","author":"Dao Thi","year":"2020","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100157_bib515","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.3390\/cells11244117","article-title":"Hepatic polarized differentiation promoted the maturity and liver function of human embryonic stem cell-derived hepatocytes via activating hippo and AMPK signaling pathways","volume":"11","author":"Wang","year":"2022","journal-title":"Cells"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100157_bib516","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1089\/scd.2017.0023","article-title":"A scalable approach for the generation of human pluripotent stem cell-derived hepatic organoids with sensitive hepatotoxicity features","volume":"26","author":"Sgodda","year":"2017","journal-title":"Stem Cells Dev"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib517","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1007\/s00204-018-2280-2","article-title":"3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo","volume":"92","author":"Rashidi","year":"2018","journal-title":"Arch Toxicol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib518","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2018.12.028","article-title":"Generation of hepatobiliary organoids from human induced pluripotent stem cells","volume":"70","author":"Wu","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib519","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2020.06.010","article-title":"Human pluripotent stem cell-derived organoids as models of liver disease","volume":"159","author":"Ramli","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib520","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19469-x","article-title":"Construction of a culture protocol for functional bile canaliculi formation to apply human iPS cell-derived hepatocytes for cholestasis evaluation","volume":"12","author":"Horiuchi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100157_bib521","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-0716-2557-6_4","article-title":"Induction of bile canaliculi-forming hepatocytes from human pluripotent stem cells","volume":"2544","author":"Matakovic","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib522","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","article-title":"High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids","volume":"160","author":"Shinozawa","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib523","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s12276-023-01074-1","article-title":"Scalable production of tissue-like vascularized liver organoids from human PSCs","volume":"55","author":"Harrison","year":"2023","journal-title":"Exp Mol Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib524","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/hep.27621","article-title":"Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro","volume":"61","author":"Berger","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib525","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.1038\/s41467-025-63323-3","article-title":"Recapitulating dengue virus infection with human pluripotent stem cell-derived liver organoids for antiviral screening","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib526","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib527","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00204-016-1838-0","article-title":"Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro","volume":"91","author":"Cipriano","year":"2017","journal-title":"Arch Toxicol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib528","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41401-018-0170-z","article-title":"Chemical cocktails enable hepatic reprogramming of human urine-derived cells with a single transcription factor","volume":"40","author":"Tang","year":"2019","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib529","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41422-019-0196-x","article-title":"A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts","volume":"29","author":"Xie","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib530","doi-asserted-by":"crossref","DOI":"10.1038\/srep38694","article-title":"Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: a novel in vitro cholestatic model","volume":"6","author":"Ni","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib531","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jhep.2019.03.031","article-title":"Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity","volume":"71","author":"Overeem","year":"2019","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib532","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.3390\/ijms23094518","article-title":"Comparative study of starch phosphorylase genes and encoded proteins in various monocots and dicots with emphasis on maize","volume":"23","author":"Yu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib533","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1038\/s41598-019-39400-1","article-title":"A proteomic time course through the differentiation of human induced pluripotent stem cells into hepatocyte-like cells","volume":"9","author":"Hurrell","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib534","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103303","article-title":"Synthetic liver fibrotic niche extracts achieve in vitro hepatoblasts phenotype enhancement and expansion","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib535","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/hepr.13893","volume":"53","author":"Danoy","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.pharmr.2026.100157_bib536","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1594340","article-title":"Comparative analysis of small molecule and growth factor-derived human induced pluripotent stem cell-derived hepatocyte-like cells","volume":"13","author":"Asumda","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.pharmr.2026.100157_bib537","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.dib.2015.10.023","article-title":"Profile of inflammation-associated genes during hepatic differentiation of human pluripotent stem cells","volume":"5","author":"Ignatius Irudayam","year":"2015","journal-title":"Data Brief"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib538","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cels.2020.11.002","article-title":"Gene regulatory network analysis and engineering directs development and vascularization of multilineage human liver organoids","volume":"12","author":"Velazquez","year":"2021","journal-title":"Cell Syst"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib539","first-page":"634","article-title":"Multidrug resistance p-glycoprotein 2 is essential for the biliary excretion of indocyanine green","volume":"29","author":"Huang","year":"2001","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib540","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jhep.2010.07.047","article-title":"Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green","volume":"54","author":"de Graaf","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib541","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.102.044107","article-title":"Pharmacokinetics of 5 (and 6)-carboxy-2\u2032,7\u2032-dichlorofluorescein and its diacetate promoiety in the liver","volume":"304","author":"Zamek-Gliszczynski","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib542","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1172\/JCI43122","article-title":"Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells","volume":"120","author":"Rashid","year":"2010","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib543","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/hep.25871","article-title":"JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia","volume":"56","author":"Cayo","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib544","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s12033-012-9635-3","article-title":"Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-induced pluripotent stem cells","volume":"54","author":"Fattahi","year":"2013","journal-title":"Mol Biotechnol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib545","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.stem.2017.01.011","article-title":"A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia","volume":"20","author":"Cayo","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib546","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13287-019-1342-6","article-title":"Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR\/Cas-mediated genetic correction, and productive hepatitis C virus infection","volume":"10","author":"Caron","year":"2019","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib547","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/hep.26237","article-title":"Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells","volume":"57","author":"Choi","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib548","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hep.27753","article-title":"Induced pluripotent stem cells model personalized variations in liver disease resulting from \u03b11-antitrypsin deficiency","volume":"62","author":"Tafaleng","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib549","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.stemcr.2015.02.021","article-title":"Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells","volume":"4","author":"Wilson","year":"2015","journal-title":"Stem Cell Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib550","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.stemcr.2014.03.014","article-title":"Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells","volume":"2","author":"Maetzel","year":"2014","journal-title":"Stem Cell Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib551","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/stem.1917","article-title":"HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells","volume":"33","author":"Soga","year":"2015","journal-title":"Stem Cells"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib552","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41422-019-0242-8","article-title":"Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib553","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.261961","article-title":"Generation and characterization of mature hepatocyte organoids for liver metabolic studies","volume":"137","author":"Liu","year":"2024","journal-title":"J Cell Sci"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100157_bib554","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/hmg\/ddr223","article-title":"Rescue of ATP7B function in hepatocyte-like cells from Wilson\u2019s disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin","volume":"20","author":"Zhang","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib555","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1073\/pnas.1121400109","article-title":"Modeling hepatitis C virus infection using human induced pluripotent stem cells","volume":"109","author":"Schwartz","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100157_bib556","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12985-016-0519-1","article-title":"A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host","volume":"13","author":"Sa-Ngiamsuntorn","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.pharmr.2026.100157_bib557","doi-asserted-by":"crossref","DOI":"10.1038\/srep36077","article-title":"Ductular reaction-on-a-chip: microfluidic co-cultures to study stem cell fate selection during liver injury","volume":"6","author":"Haque","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100157_bib558","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152667","article-title":"A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate\u00ae","volume":"450","author":"Bircsak","year":"2021","journal-title":"Toxicology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib559","doi-asserted-by":"crossref","DOI":"10.1063\/5.0210955","article-title":"Hepatic spheroid-on-a-chip: fabrication and characterization of a spheroid-based in vitro model of the human liver for drug screening applications","volume":"18","author":"AlShmmari","year":"2024","journal-title":"Biomicrofluidics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib560","first-page":"1","article-title":"The role of liver zonation in physiology, regeneration, and disease","volume":"42","author":"Panday","year":"2022","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib561","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.32408","article-title":"Liver zonation, revisited","volume":"76","author":"Paris","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib562","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jhep.2021.04.048","article-title":"Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code","volume":"75","author":"Rombaut","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib563","doi-asserted-by":"crossref","first-page":"345","DOI":"10.33594\/000000662","article-title":"Induced pluripotent stem cells (Ipscs) based liver organoid: the benefits and challenges","volume":"57","author":"Septiana","year":"2023","journal-title":"Cell Physiol Biochem"},{"issue":"suppl","key":"10.1016\/j.pharmr.2026.100157_bib564","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.3350\/cmh.2024.1040","article-title":"Liver organoids: current advances and future applications for hepatology","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"8065","key":"10.1016\/j.pharmr.2026.100157_bib565","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41586-025-08850-1","article-title":"Multi-zonal liver organoids from human pluripotent stem cells","volume":"641","author":"Reza","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib566","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13287-025-04139-2","article-title":"Advances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling","volume":"16","author":"Shao","year":"2025","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib567","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cmet.2019.05.007","article-title":"Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids","volume":"30","author":"Ouchi","year":"2019","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib568","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/HEP.0000000000000683","article-title":"A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression","volume":"80","author":"Lee","year":"2024","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib569","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.stemcr.2017.06.010","article-title":"An in vitro human liver model by iPSC-derived parenchymal and non-parenchymal cells","volume":"9","author":"Koui","year":"2017","journal-title":"Stem Cell Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100157_bib570","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.celrep.2017.11.005","article-title":"Massive and reproducible production of liver buds entirely from human pluripotent stem cells","volume":"21","author":"Takebe","year":"2017","journal-title":"Cell Rep"},{"issue":"6751","key":"10.1016\/j.pharmr.2026.100157_bib571","doi-asserted-by":"crossref","DOI":"10.1126\/science.adu9375","article-title":"Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization","volume":"388","author":"Abilez","year":"2025","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib572","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41551-025-01416-6","article-title":"Self-organization of sinusoidal vessels in pluripotent stem cell-derived human liver bud organoids","volume":"9","author":"Saiki","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib573","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acs.molpharmaceut.5c01122","article-title":"Liver-on-a-chip (LoC) models: case studies of academic platforms and commercial products","volume":"23","author":"Benzait","year":"2026","journal-title":"Mol Pharm"},{"key":"10.1016\/j.pharmr.2026.100157_bib574","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2025.101462","article-title":"Ex vivo culture models to study viral infections of the liver","volume":"71","author":"F\u00f6derl-H\u00f6benreich","year":"2025","journal-title":"Curr Opin Virol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100157_bib575","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1039\/D2LC00307D","article-title":"Liver organ-on-chip models for toxicity studies and risk assessment","volume":"22","author":"Messelmani","year":"2022","journal-title":"Lab Chip"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100157_bib576","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41575-020-00386-1","article-title":"Human biomimetic liver microphysiology systems in drug development and precision medicine","volume":"18","author":"Gough","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib577","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1039\/C9LC00768G","article-title":"Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry","volume":"20","author":"Baudy","year":"2020","journal-title":"Lab Chip"},{"key":"10.1016\/j.pharmr.2026.100157_bib578","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tiv.2017.01.007","article-title":"Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity","volume":"40","author":"Chang","year":"2017","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib579","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41598-025-31044-8","article-title":"3D co-cultures of primary human hepatocytes and Kupffer-like cells to address innate immune responses to rAAV","volume":"16","author":"Ramella Gal","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib580","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s42003-021-02616-x","article-title":"Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system","volume":"4","author":"Kostrzewski","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib581","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep4.1450","article-title":"A microphysiological system for studying nonalcoholic steatohepatitis","volume":"4","author":"Kostrzewski","year":"2020","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib582","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/tee.24054","article-title":"On-chip differentiation of hepatic cords with radial flow","volume":"19","author":"Rajendran","year":"2024","journal-title":"IEEJ Trans Electr Electron Eng"},{"key":"10.1016\/j.pharmr.2026.100157_bib583","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biomaterials.2015.08.043","article-title":"A microfluidically perfused three dimensional human liver model","volume":"71","author":"Rennert","year":"2015","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib584","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92011-7","article-title":"A versatile microfluidic tool for the 3D culture of HepaRG cells seeded at various stages of differentiation","volume":"11","author":"Boul","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100157_bib585","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100187","article-title":"Microphysiological systems as an emerging in vitro approach for the evaluation of drug absorption, distribution, metabolism, and excretion and toxicity","volume":"53","author":"Shrimali","year":"2025","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100157_bib586","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cpt.2627","article-title":"New and emerging research on solute carrier and ATP binding cassette transporters in drug discovery and development: outlook from the international transporter consortium","volume":"112","author":"Giacomini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100157_bib587","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1124\/dmd.118.082750","article-title":"Perspective on the application of microphysiological systems to drug transporter studies","volume":"46","author":"Caetano-Pinto","year":"2018","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib588","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/cpt.436","article-title":"Liver and kidney on chips: microphysiological models to understand transporter function","volume":"100","author":"Chang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100157_bib589","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/adc3ce","article-title":"A hollow fiber membrane-based liver organoid-on-a-chip model for examining drug metabolism and transport","volume":"17","author":"Myszczyszyn","year":"2025","journal-title":"Biofabrication"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100157_bib590","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/s12248-023-00870-x","article-title":"A novel milli-fluidic liver tissue chip with continuous recirculation for predictive pharmacokinetics applications","volume":"25","author":"Rajan","year":"2023","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100157_bib591","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/00498254.2014.944612","article-title":"Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device","volume":"45","author":"Vivares","year":"2015","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100157_bib592","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/ten.tec.2010.0580","article-title":"Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies","volume":"17","author":"Zeilinger","year":"2011","journal-title":"Tissue Eng C"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100157_bib593","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1021\/acsbiomaterials.3c00346","article-title":"Development of an induced pluripotent stem cell-based liver-on-a-chip assessed with an Alzheimer\u2019s disease drug","volume":"9","author":"Fanizza","year":"2023","journal-title":"ACS Biomater Sci Eng"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100157_bib594","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1039\/C6LC00598E","article-title":"Engineering a perfusable 3D human liver platform from iPS cells","volume":"16","author":"Schepers","year":"2016","journal-title":"Lab Chip"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100157_bib595","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1039\/C8LC00869H","article-title":"In situ differentiation and generation of functional liver organoids from human iPSCs in a 3D perfusable chip system","volume":"18","author":"Wang","year":"2018","journal-title":"Lab Chip"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100157_bib596","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3390\/cells12192368","article-title":"Improvements in maturity and stability of 3D iPSC-derived hepatocyte-like cell cultures","volume":"12","author":"Suominen","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100157_bib597","article-title":"Novel vascularized human liver organoids for modeling alcohol-induced liver injury and developing hepatoprotective therapy","volume":"13","author":"Yang","year":"2026","journal-title":"Adv Sci (Weinh)"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:16:05Z","timestamp":1789121765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":595,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0031699726000451"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100157","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of human liver cell models in drug development and toxicity studies: The role of membrane transporters","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100157"}}